Gary Hudes
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia
USA
Name/email consistency: high
- Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. Hudes, G., Haas, N., Yeslow, G., Gillon, T., Gunnarsson, P.O., Ellman, M., Nordle, O., Eriksson, B., Miller, L., Cisar, L., Kopreski, M., Viaro, D., Hartley-Asp, B. J. Clin. Oncol. (2002)
- Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Hudes, G.R., Szarka, C.E., Adams, A., Ranganathan, S., McCauley, R.A., Weiner, L.M., Langer, C.J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., Gallo, J.M. Clin. Cancer Res. (2000)
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Hudes, G.R., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., Ross, E., Roethke, S., McAleer, C. J. Clin. Oncol. (1997)